Suven Pharma Soars to New Heights With USFDA's 'VAI' Tag For Hyderabad Facility

Suven Pharmaceuticals’ share price soared by up to 3.67% on Monday, reaching an unprecedented Rs 1,245 per share on the BSE. This significant spike follows the company’s announcement on Sunday that its subsidiary's Hyderabad manufacturing facility has been awarded a ‘Voluntary Action Indicated’ (VAI) status by the US FDA. 

The inspection, conducted at Casper Pharma’s formulations facility in Hyderabad, has been officially marked as ‘closed’ by the US FDA, as confirmed in the company's exchange filing. The US FDA’s ‘Voluntary Action Indicated’ (VAI) designation means that although some issues or practices were found during the inspection, the FDA is not recommending any formal actions. Instead, the facility is expected to independently address and resolve these concerns.

Founded in 2018, Suven Pharmaceuticals is a biopharmaceutical firm focused on creating and manufacturing new chemical entity (NCE) intermediates, active pharmaceutical ingredients (APIs), specialty chemicals, and formulated drugs. As a contract development and manufacturing organization (CDMO), Suven Pharmaceuticals provides essential support for global pharmaceutical, biotechnology, and chemical companies in their NCE development processes.